Jotun supports the COVAX programme to help the fight against the pandemic

In the fight against Covid-19 Jotun has donated NOK 5 million to Unicef and the COVAX programme.

Vaccinating the world against this coronavirus disease will be the largest vaccine procurement and supply operation in history. Jotun wants to contribute by supporting UNICEF and partners who are working around the clock to ensure that no country is left behind.

COVAX is the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator. The ACT Accelerator is a ground-breaking global collaboration to accelerate the development, production, and equitable access to COVID-19 tests, treatments, and vaccines.

COVAX is co-led by Coalition for Epidemic Preparedness Innovations (CEPI), Gavi and WHO. UNICEF has been given a very important role with responsibility for purchasing, storing and transporting the vaccines to 92 countries that are considered low- or middle-income countries.

Its aim is to accelerate the development and manufacture of COVID-19 vaccines, and to guarantee fair and equitable access for every country in the world.

Why do we need COVAX
Developing a vaccine against COVID-19, is the most pressing challenge of our time - and nobody wins the race until everyone wins.

The global pandemic has already caused the loss of hundreds of thousands of lives and disrupted the lives of billions more.

As well as reducing the tragic loss of life and helping to get the pandemic under control, the introduction of a vaccine will prevent the huge losses to the global economy every month.

Global equitable access to a vaccine, particularly protecting health care workers and those most at risk is the only way to mitigate the public health and economic impact of the pandemic.
Other CR initiatives
In addition to supporting Unicef, the Jotun Group as donated NOK 1 million to Red Cross / Red Crescent and their work to fight the pandemic in India.

During the last year several of our 67 Jotun companies have arranged local CR initiatives related to Covid-19.

The vaccine journey/Unicef